You are currently using an unsupported browser which could affect the appearance and functionality of this website. Please consider upgrading to the latest version or using alternatives such as Mozilla Firefox, Google Chrome or Microsoft Edge.

Obstetric Cholestasis (Green-top Guideline No. 43)

Summary

In England, obstetric cholestasis (also referred to as intrahepatic cholestasis of pregnancy) affects 0.7% of pregnancies in multiethnic populations and 1.2–1.5% of women of Indian–Asian or Pakistani–Asian origin. Prevalence is influenced by genetic and environmental factors and varies between populations worldwide. For example, in Chile, 2.4% of all pregnancies are affected, with a 5% prevalence in women of Araucanian–Indian origin.

Obstetric cholestasis is a multifactorial condition of pregnancy characterised by pruritus in the absence of a skin rash with abnormal liver function tests (LFTs), neither of which has an alternative cause and both of which resolve after birth. The clinical importance of obstetric cholestasis lies in the potential fetal risks, which may include spontaneous preterm birth, iatrogenic preterm birth and fetal death. There can also be maternal morbidity in association with the intense pruritus and consequent sleep deprivation.

This guideline summarises the evidence for the fetal risks associated with obstetric cholestasis and provides guidance on the different management choices and the options available for its treatment.The wide range of definitions of obstetric cholestasis and the absence of agreed diagnostic criteria make comparisons of the published literature challenging and limit the ability to provide detailed recommendations for specific aspects of care. Areas of uncertainty are highlighted along with recommendations for future research in this field.


COVID disclaimer

This guideline was developed as part of the regular programme of Green-top Guidelines, as outlined in our document Developing a Green-top Guideline: Guidance for developers (PDF), and prior to the emergence of COVID-19.

Version history

This is the second edition of this guideline; the third edition is currently in development.

Developer declaration of interests

Available on request.

This page was last reviewed 19 May 2011.